Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria

Infectious Agents and Cancer

Volumn 12, Issue 1, 2017, Pages 1-9

  Modibbo, Fatima ^a   Iregbu, K C ^a   Okuma, James ^b   Leeman, Annemiek ^c   Kasius, Annemieke ^c   De Koning, Maurits ^c   Quint, Wim ^c   Adebamowo, Clement ^d,e  

^a NATIONAL HOSPITAL   (Nigeria)

^b INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

^c Manager Development and Diagnostic Services (DDS)   (Netherlands)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cervical cancer; Human papillomavirus; Randomized trial; Screening; Self sampling

Indexed keywords

GENOMIC DNA; RIBONUCLEASE P;

ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INFORMED CONSENT; INTENTION TO TREAT ANALYSIS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NIGERIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RNASE P GENE; URBAN AREA; UTERINE CERVIX CANCER;

EID: 85011591006     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-017-0123-z     Document Type: Article

References (40)

1. Iarc. Cancer Fact Sheet: Who; 2012. Available From: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp. Accessed 6 Feb 2016.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer Incidence And Mortality Worldwide: Sources, Methods And Major Patterns In Globocan 2012. International Journal Of Cancer Journal International Du Cancer. 2015;136(5):E359-86.
3. Jedy-Agba E, Curado M, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, et al. Cancer Incidence In Nigeria: A Report From Population-Based Cancer Registries. Cancer Epidemiol. 2012;36(5):E271-8.
4. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M, et al. Overview Of Human Papillomavirus-Based And Other Novel Options For Cervical Cancer Screening In Developed And Developing Countries. Vaccine. 2008;26 Suppl 10:K29-41.
5. Kahesa C, Kjaer S, Mwaiselage J, Ngoma T, Tersbol B, Dartell M, et al. Determinants Of Acceptance Of Cervical Cancer Screening In Dar Es Salaam, Tanzania. BMC Public Health. 2012;12:1093.
6. Mupepi S, Sampselle C, Johnson T. Knowledge, Attitudes, And Demographic Factors Influencing Cervical Cancer Screening Behavior Of Zimbabwean Women. Journal Of Women's Health (2002). 2011;20(6):943-52.
7. Mbamara S, Oc I, Je O, Iv O, Co U. Knowledge, Attitude And Practice Of Cervical Cancer Screening Among Women Attending Gynecology Clinics In A Tertiary Level Medical Care Center In Southeastern Nigeria. The Journal Of Reproductive Medicine. 2011;56(11-12):491-6.
8. Sankaranarayanan R, Nene B, Shastri SS, Jayant K, Muwonge R, Budukh A, et al. Hpv Screening For Cervical Cancer In Rural India. The New England Journal Of Medicine. 2009;360(14):1385-94.
9. Ononogbu U, Almujtaba M, Modibbo F, Lawal I, Offiong R, Olaniyan O, et al. Cervical Cancer Risk Factors Among Hiv-Infected Nigerian Women. BMC Public Health. 2013;13(1):582.
10. Jd G-F, Nk S, Ja S, Km K, Sj G. Cost-Effectiveness Of Cervical Cancer Screening With Human Papillomavirus Dna Testing And Hpv-16,18 Vaccination. Journal Of The National Cancer Institute. 2008;100(5):308-20.
11. Isa Modibbo F, Dareng E, Bamisaye P, Jedy-Agba E, Adewole A, Oyeneyin L, et al. Qualitative Study Of Barriers To Cervical Cancer Screening Among Nigerian Women. BMJ Open. 2016;6(1):E008533.
12. Kling M, Zeichner JA. The Role Of The Human Papillomavirus (Hpv) Vaccine In Developing Countries. International Journal Of Dermatology. 2010;49(4):377-9.
13. Nigeria Fr. Legal Notice On Publication Of 2006 Census Final Results In: Centre. Pala, Editor. Abuja2009. P. B1-42
14. Hantz S, Goudard M, Marczuk V, Renaudie J, Dussartre C, Bakeland D, et al. Hpv Detection And Typing By Inno-Lipa Assay On Liquid Cytology Media Easyfix Labonord After Extraction Qiaamp Dna Blood Mini Kit Qiagen And Nuclisens Easymag Biomerieux. Pathol Biol. 2010;58(2):179-83.
15. Geraets D, Cuschieri K, De Koning M, Van Doorn L, Snijders P, Meijer C, et al. Clinical Evaluation Of A Gp5+/6+−Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability And An Internal Control. Journal Of Clinical Microbiology. 2014;52(11):3996-4002.
16. Luo W, Yang H, Rathbun K, Pau C, Ou C. Detection Of Human Immunodeficiency Virus Type 1 Dna In Dried Blood Spots By A Duplex Real-Time Pcr Assay. Journal Of Clinical Microbiology. 2005;43(4):1851-7.
17. Pa H, Taylor R, Thielke R, Payne J, Gonzalez N, Jg C. Research Electronic Data Capture (Redcap)--A Metadata-Driven Methodology And Workflow Process For Providing Translational Research Informatics Support. Journal Of Biomedical Informatics. 2009;42(2):377-81.
18. Filmer D, Pritchett L. Estimating Wealth Effects Without Expenditure Data--Or Tears: An Application To Educational Enrollments In States Of India. Demography. 2001;38(1):115-32.
19. Bansil P, Wittet S, Lim J, Winkler J, Paul P, Jeronimo J. Acceptability Of Self-Collection Sampling For Hpv-Dna Testing In Low-Resource Settings: A Mixed Methods Approach. BMC Public Health. 2014;14:596.
20. Crofts V, Flahault E, Tebeu P, Untiet S, Fosso G, Boulvain M, et al. Education Efforts May Contribute To Wider Acceptance Of Human Papillomavirus Self-Sampling. International Journal Of Women's Health. 2015;7:149-54.
21. Pj S, Vm V, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-Risk Hpv Testing On Self-Sampled Versus Clinician-Collected Specimens: A Review On The Clinical Accuracy And Impact On Population Attendance In Cervical Cancer Screening. International Journal Of Cancer Journal International Du Cancer. 2013;132(10):2223-36.
22. Af R, Gatuguta A, Choi R, Guthrie B, Mackelprang R, Bosire R, et al. Knowledge And Acceptability Of Pap Smears, Self-Sampling And Hpv Vaccination Among Adult Women In Kenya. Plos One. 2012;7(7):E40766.
23. Cw N, Boga H, Aw M, Wanzala P, Jn M. Factors Affecting Uptake Of Cervical Cancer Early Detection Measures Among Women In Thika, Kenya. Health Care For Women International. 2012;33(7):595-613.
24. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening For Cervical Cancer In Developing Countries. Vaccine. 2006;24 Suppl 3:S3/71-7.
25. Szarewski A, Cadman L, Ashdown-Barr L, Waller J. Exploring The Acceptability Of Two Self-Sampling Devices For Human Papillomavirus Testing In The Cervical Screening Context: A Qualitative Study Of Muslim Women In London. Journal Of Medical Screening. 2009;16(4):193-8.
26. Lack N, West B, Jeffries D, Ekpo G, Morison L, Soutter W, et al. Comparison Of Non-Invasive Sampling Methods For Detection Of Hpv In Rural African Women. Sex Transm Infect. 2005;81(3):239-41.
27. Van Baars R, Bosgraaf R, Ter Harmsel B, Melchers W, Quint W, Bekkers R. Dry Storage And Transport Of A Cervicovaginal Self-Sample By Use Of The Evalyn Brush, Providing Reliable Human Papillomavirus Detection Combined With Comfort For Women. Journal Of Clinical Microbiology. 2012;50(12):3937-43.
28. Akarolo-Anthony S, Famooto A, Dareng E, Olaniyan O, Offiong R, Wheeler C, et al. Age-Specific Prevalence Of Human Papilloma Virus Infection Among Nigerian Women. BMC Public Health. 2014;14:656.
29. Akarolo-Anthony S, Al-Mujtaba M, Famooto A, Dareng E, Olaniyan O, Offiong R, et al. Hiv Associated High-Risk Hpv Infection Among Nigerian Women. BMC Infect Dis. 2013;13:521.
30. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. Human Papillomavirus And Related Diseases. In: The World.: Ico Information Centre On Hpv And Cancer (Hpv Information Centre). 2016.
31. Piras F, Piga M, De Montis A, Zannou A, Minerba L, Perra M. Prevalence Of Human Papillomavirus Infection In Women In Benin, West Africa. Virol J. 2011;8:514.
32. Keita N, Clifford G, Koulibaly M, Douno K, Kabba I, Haba M, et al. Hpv Infection In Women With And Without Cervical Cancer In Conakry, Guinea. British Journal Of Cancer. 2009;101(1):202-8.
33. Castellsague X, Menendez C, Loscertales Mp Jr K, Dos Santos F, Gomez-Olive F, et al. Human Papillomavirus Genotypes In Rural Mozambique. Lancet. 2001;358(9291):1429-30.
34. Nweke G, Banjo Aaf, Abdulkareem Fb, Nwadike Vu. Prevalence Of Human Papilloma Virus Dna In Hiv Positive Women In Lagos University Teaching Hospital (Luth) Lagos, Nigeria British Microbiology Research Journal. 2012;3(3).
35. Jc G, Ko A, Na W, Ac A, Eklund C, Reilly M, et al. The Age-Specific Prevalence Of Human Papillomavirus And Risk Of Cytologic Abnormalities In Rural Nigeria: Implications For Screen-And-Treat Strategies. International Journal Of Cancer Journal International Du Cancer. 2012;130(9):2111-7.
36. Gm C, Gallus S, Herrero R, Munoz N, Pj S, Vaccarella S, et al. Worldwide Distribution Of Human Papillomavirus Types In Cytologically Normal Women In The International Agency For Research On Cancer Hpv Prevalence Surveys: A Pooled Analysis. Lancet. 2005;366(9490):991-8.
37. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F, De Sanjose S. Cervical Human Papillomavirus Prevalence In 5 Continents: Meta-Analysis Of 1 Million Women With Normal Cytological Findings. The Journal Of Infectious Diseases. 2010;202(12):1789-99.
38. Tourangeau R, Yan T. Sensitive Questions In Surveys. Psychol Bull. 2007;133(5):859-83.
39. Bader F, Bauer J, Kroher M, Riordan P. Privacy Concerns In Responses To Sensitive Questions: A Survey Experiment On The Influence Of Numeric Codes On Unit Nonresponse, Item Nonresponse, And Misreporting Methods, Data, Analyses : A Journal For Quantitative Methods And Survey Methodology (Mda).10:47-72
40. Nigeria Demographic And Health Survey 2013. Abuja, Nigeria, And Rockville, Maryland, Usa: Npc And Icf International: National Population Commission (Npc) [Nigeria] Icf International; 2014